Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
35.22
+1.47 (4.36%)
Feb 21, 2025, 4:00 PM EST - Market closed
Agios Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 36.5 | 26.82 | 14.24 | - | - | Upgrade
|
| Revenue Growth (YoY) | 36.07% | 88.36% | - | - | - | Upgrade
|
| Cost of Revenue | 305.45 | 298.41 | 281.61 | 256.97 | 220.81 | Upgrade
|
| Gross Profit | -268.95 | -271.58 | -267.37 | -256.97 | -220.81 | Upgrade
|
| Selling, General & Admin | 156.78 | 119.9 | 121.67 | 121.45 | 115.11 | Upgrade
|
| Operating Expenses | 156.78 | 119.9 | 121.67 | 121.45 | 115.11 | Upgrade
|
| Operating Income | -425.74 | -391.49 | -389.05 | -378.42 | -335.92 | Upgrade
|
| Interest & Investment Income | 48.08 | 33.34 | 12.79 | 0.84 | 6.61 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.49 | 6.06 | 16.6 | 21.07 | - | Upgrade
|
| EBT Excluding Unusual Items | -371.17 | -352.09 | -359.65 | -356.51 | -329.31 | Upgrade
|
| Gain (Loss) on Sale of Assets | 200 | - | - | - | - | Upgrade
|
| Other Unusual Items | 889.14 | - | 127.85 | - | - | Upgrade
|
| Pretax Income | 717.97 | -352.09 | -231.8 | -356.51 | -329.31 | Upgrade
|
| Income Tax Expense | 44.24 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 673.73 | -352.09 | -231.8 | -356.51 | -329.31 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | 1,961 | 1.94 | Upgrade
|
| Net Income | 673.73 | -352.09 | -231.8 | 1,605 | -327.37 | Upgrade
|
| Net Income to Common | 673.73 | -352.09 | -231.8 | 1,605 | -327.37 | Upgrade
|
| Shares Outstanding (Basic) | 57 | 56 | 55 | 60 | 69 | Upgrade
|
| Shares Outstanding (Diluted) | 58 | 56 | 55 | 60 | 69 | Upgrade
|
| Shares Change (YoY) | 4.02% | 1.57% | -9.36% | -12.39% | 15.01% | Upgrade
|
| EPS (Basic) | 11.86 | -6.33 | -4.23 | 26.55 | -4.74 | Upgrade
|
| EPS (Diluted) | 11.64 | -6.33 | -4.23 | 26.55 | -4.74 | Upgrade
|
| Free Cash Flow | -391.53 | -297.06 | -314.36 | -413.06 | -304.87 | Upgrade
|
| Free Cash Flow Per Share | -6.76 | -5.34 | -5.74 | -6.83 | -4.42 | Upgrade
|
| Operating Margin | -1166.47% | -1459.52% | -2732.07% | - | - | Upgrade
|
| Profit Margin | 1845.92% | -1312.63% | -1627.82% | - | - | Upgrade
|
| Free Cash Flow Margin | -1072.73% | -1107.49% | -2207.58% | - | - | Upgrade
|
| EBITDA | -420.08 | -384.86 | -380.48 | -369.18 | -326.13 | Upgrade
|
| D&A For EBITDA | 5.65 | 6.62 | 8.56 | 9.24 | 9.79 | Upgrade
|
| EBIT | -425.74 | -391.49 | -389.05 | -378.42 | -335.92 | Upgrade
|
| Effective Tax Rate | 6.16% | - | - | - | - | Upgrade
|
| Revenue as Reported | 36.5 | 26.82 | 14.24 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.